ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease

ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease.

The success of Angiotensin-converting enzyme (ACE) inhibitors in preventing the progression of chronic renal insufficiency has led investigators to study the effects of other inhibitors of the renin-angiotensin system (RAS). Recently, the results of the first large-scale trials with angiotensin II type 1 receptor (AT1) antagonists became available (1,2). This article discusses the relative meri...

Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease?

At the present time we cannot assume that the proven benefits of ACEI on renal disease will be reproduced by using AT1-ra. With potentially differing modes of activity of these drugs, they cannot be seen as interchangeable and ACEI should remain the drug of choice in patients with progressive renal disease unless they are not tolerated. It is possible that AT1-ra may offer additional advantages...

ACE inhibitors, angiotensin receptor antagonists and bradykinin.

Meta-Analysis of Combined Therapy with Angiotensin Receptor Antagonists versus ACE Inhibitors Alone in Patients with Heart Failure

BACKGROUND There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure. METHODOLOGY/PRINCIPAL FINDINGS Two independent reviewers searched and abstracted randomized controlled trials of ARBs and ACE inhibitors compared to ACE ...

Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis.

Chronic kidney disease (CKD) is a public health priority. The unadjusted mortality rate of end-stage renal disease (ESRD) is 29% at 2 years and 52% at 5 years. ESRD is associated with cardiovascular (CV) morbidity and mortality 2 to 10 times that of a population with normal renal function. Heart disease is the leading cause of mortality in patients on hemodialysis (HD) (42% of total mortality) ...